Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q3 2021 Earnings Presentation
16 slides from Expres2ion Biotech Holding Ab's earnings presentation, Nov 18, 2021
Slide 1: Q3 2021 Financial Report
Q3 2021 Financial Report November 18, 2021 Proteins for Life Bent U. Frandsen, CEO Keith Alexander, CFO
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this pre
Slide 3: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress DISEASE Project/Target Discovery Pre-clinical cGMP / Tox Phase 1 Phase 2 Phase 3 Market Partner/Funding Pharmacology Potential > 30 Coronavirus ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II I/IIa BN: II billion EUR PREVENT-nCoV > 10 100%
Slide 4: ABNCoV2 COVID-19 Vaccine Update (I)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine Update (I) Update on Phase I/IIa trial confirms safety and tolerability and excellent efficacy profile ABNCoV2 induces high neutralisation titers Strong cross neutralization of variants • Dose response: increased titers with higher vaccine doses up to 25 mg, • No
Slide 5: ABNCoV2 COVID-19 Vaccine Update (II)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine Update (II) Bavarian Nordic carries on with the Phase II trial, and granted 800 MDKK funding for Phase III Proteins for Life |5
Slide 6: ES2B-C001 HER2+ Cancer Vaccine Update
BREAST CANCER ES2B-C001 HER2+ Cancer Vaccine Update Progression as planned towards first in human trial in 2023 Q2 2021 Q4 2021 End 2022 / Early 2023 Candidate selection PoC study on-going Key milestone: Clinical trial application (CTA) filing Continued pre-clinical development PoC study headline re
Slide 7: Influenza / Malaria Vaccines Update
INFLUENZA / MALARIA Influenza / Malaria Vaccines Update Progression catching up again, after initial delay due to the COVID-19 pandemic INDIGO Flu Vaccine INDIGO • Shipped first proteins to INDIGO for testing • Both trimer (minor) and multimer (major) proteins and both have agglutination activity –
Slide 8: 2021 – 2023 Outlook
2021 – 2023 Outlook On track to deliver shareholder value 2021 2022 2023 CORONAVIRUS (ABNCoV2) Phase I/II trial, COUGH-1 COUGH-1 BN Phase II BN Phase II BN Phase III BN Phase III BN ready for COUGH-1 initial safety full safety trial trial readout trial initial market launch initiated results (Q2) &
Slide 9: Events
Events Recent and near-term events – check web-page for updates Life Science Sweden HC Andersen Capital LifeSci Advisors - HC Andersen – Q2 – The future of June - Life Science Nordic Biotech August September Results Swedish & Danish Seminar Summit Life Science HC Andersen – Økonomis Ugebrev – LSX Le
Slide 10: Q3 2021 Financial Results
Q3 2021 Financial Results Proteins for Life
Slide 11: Operating income
Operating income Operating income, SEK ‘000s Net sales, SEK ‘000s Other operating income, SEK ‘000s 6,000 5,000 5,000 4,500 5,000 4,000 4,000 4,000 3,500 3,000 = 3,000 + 3,000 2,500 2,000 2,000 2,000 1,500 1,000 1,000 1,000 500 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 0 0 Net sales O
Slide 12: COVID-19: Proceeds from AdaptVac
COVID-19: Proceeds from AdaptVac Late 2022 / early 2023 2023+ Small approval application submission milestone Sales milestones (if not all surpassed already) payment Sales royalties Monetization of AdaptVac ownership stake (34%) / royalties accumulating at AdaptVac Sales milestones (up to €2 million
Slide 13: Operating costs
Operating costs Operating costs, SEK ‘000s 3Q Operating costs, SEK ‘000s YTD Operating costs, SEK ‘000s 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 0 0 0 -2,000 -3,000 -10,000 -4,000 -6,000 -20,000 -6,000 -24,010 -9,000 -7,215 -8,000 -30,000 +73% -12,000 -10,000 +72% -40,000 -12,000 -41,508 -15,000 -12,
Slide 14: Profit / loss for the period
Profit / loss for the period 3Q profit / loss, SEK ‘000s YTD profit / loss, SEK ‘000s 2020 2021 2020 2021 0 0 -7,000 -3,000 -14,000 -4,887 -14,360 -6,000 -21,000 +92% +106% -9,000 -9,382 -28,000 -29,605 -12,000 -35,000 Proteins for Life | 14
Slide 15: Cash balance
Cash balance SEK millions 160 142 140 120 107 108 100 83 80 60 40 30 20 10 13 5 3 5 6 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 Proteins for Life | 15
Slide 16: Thank you!
Thank you! Contact: info@expreS2ionbio.com Proteins for Life 16
ExpreS2ion Biotech Holding — Q3 2021 Earnings Presentation on 6ix